BRBisharah Rizvi

Bisharah Rizvi

*This is an algorithmically generated author record based on publicly available information.

Bisharah Rizvi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Complications of linear endobronchial ultrasound guided biopsies: narrative review

    by Bisharah Rizvi, Jorge A. Munoz Pineda, Keriann Van Nostrand, Russell Miller, George Cheng, Niral M. Patel

    Background and Objective: Linear endobronchial ultrasound (EBUS) has become a key tool for diagnosing pulmonary diseases, offering high diagnostic yield for both malignant and non-malignant conditions. With its increased use, more complications are being reported. The objective of this narrative review is to discuss the complications associated with linear EBUS. Methods: A literature search using PubMed and Google Scholar from 2009 to 2024 was done. We included case reports, prospective, and retrospective studies reporting linear EBUS complications. Key Content and Findings: Overall complications from EBUS range from 0.04% to 17%. Most common are infectious complications which are 0.04–4%. These include mediastinitis, pneumonia, pericarditis, bacteremia, tumor bed infection, lung abscess, empyema, and septic shock. Other complications include pneumothorax, pneumomediastinum, pneumopericardium, pneumoperitoneum, and subcutaneous emphysema. Complications due to anesthesia or equipment malfunction can occur as well. Hemorrhagic complications have been reported as well. Mortality is low 0.01–0.04%, and four cases have been reported that led to death from complications. Conclusions: With increased use of EBUS as a diagnostic tool, number of complications will increase. Clinicians performing the procedures should be aware of types of possible complications that can occur and follow the patients closely after the procedure. Rapid diagnosis and treatment should be done to avoid fatal outcomes.


  • Open Access

    Depression Paradox in Cardiovascular Outcomes of Adult Patients with Obstructive Sleep Apnea: Insights from 2 Million Nationwide Hospitalizations

    by Rupak Desai, Sashwath Srikanth, Shaylika Chauhan, Zainab Gandhi, Warda Shahnawaz, Aleen Rahman, Bisharah Rizvi, Akhil Jain

    Depression Paradox in Cardiovascular Outcomes of Adult Patients with Obstructive Sleep Apnea: Insights from 2 Million Nationwide Hospitalizations - Thoracic Research and Practice


  • Open Access

    Prevalence and impact of tobacco use disorder on in-hospital mortality in patients hospitalized with non-group 1 pulmonary hypertension

    by Rupak Desai, Zainab Gandhi, Saher Taj Shiza, Akhil Jain, Hiren Koshiya, Bibi Alli-Ramsaroop, Agatha Olawunmi Akinsete, Eko Wilson, Pranathi Rudra, Mohan Sai Sunith Vegesna, et al.

    Numerous studies indicated that patients with tobacco use disorder (TUD) are inversely associated with mortality in what is known as the smoker's paradox. However, limited studies have been conducted on the impact of TUD on the in-hospital mortality rates of patients with secondary pulmonary hypertension (PH, Non-Group 1 PH). Using the 2019 National Inpatient Sample, we identified PH and divided it into TUD and non-TUD to compare the comorbidities and in-hospital mortality between the two after 1:1 propensity-score matching. Of 1,129,440 PH hospitalizations, 12.1 % had TUD. After matching (n=133545, each group), TUD had lower median age (62 vs. 63), higher females (49 vs. 46.6 %), blacks (25.9 vs. 25.3 %), lower household income (40.8 vs. 32.7 %), Medicaid (22.4 vs. 14.8 %), non-elective (93.5 vs. 89.8 %), rural (9.3 vs. 6.7 %), urban non-teaching (17.2 vs 15.8 %) admissions. All CV comorbidities and other substance use were higher in TUD except CHF and valvular heart disease, TUD+ cohort and lower mortality (3.3 vs. 4.2 %, OR 0.78, p<0.001), higher routine discharges (53.8 vs. 51.3 %, p<0.001) and lower total charges ($47155 vs. 51909, p<0.001) than non-TUD. Although PH patients with TUD had a higher comorbidity burden, they had lower in-hospital mortality rates along with lower total charges of hospitalization, mandating real-world data to validate these results.